Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans

Drug Metabolism and Disposition

Volumn 28, Issue 7, 2000, Pages 772-780

  Cox, Peter J ^a   Ryan, David A ^a   Hollis, Frank J ^a   Harris, Ann Marie ^a   Miller, Ann K ^a   Vousden, Marika ^a   Cowley, Hugh ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; N DEMETHYLASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMETHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISOTOPE LABELING; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033911580     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee KK and O'Rahilly S (1997) Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153.
2. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG and Leibowitz MD (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195.
3. Bolton GC, Keogh JP, East PB, Hollis FJ and Shore AD (1996) The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 26:627-636.
4. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-547.
5. Forman BM, Chen J and Evans RM (1996) The peroxisome proliferator-activated receptors: Ligand and activators. Ann NY Acad Sci 804:266-274.
6. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM and Morris DC (1996) Peroxisome proliferator-activaled receptor gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094.
7. Henry RR (1997) Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573.
8. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart J-C, Fievet C, Auwerx J and Staels B (1997) Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 17:1756-1764.
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956.
10. Martin G, Schoonjans K, Lefebvre A-M, Staels B and Auwerx J (1997) Co-ordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR alpha and PPAR gamma activators. J Biol Chem 272:28210-28217.
11. Matthews DR, Bakst A, Weston WM and Hemyari P (1999) Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 42 (Suppl 1):A228.
12. Motojima K, Passilly P, Peters JM, Gonzalez FJ and Latruffe N (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue-and inducer-specific manner. J Biol Chem 273:16710-16714.
13. Patel J, Miller E, Patwardhan R and Rosiglitazone 011 Study Group (1998) Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes 47 (Suppl 1):A17.
14. Pearson SL, Cawthorne MA, Clapham JC, Dunmore SJ, Holmes SD, Moore GBT, Smith SA and Tadayyon M (1996) The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR gamma and aP2 in adipose tissue of high-fat fed rats. Biochem Biophys Res Comm 229:752-757.
15. Perry C and Petrie JR (1998) Insulin-sensitising agents. Emerging Drugs 3:247-260.
16. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, Staels B and Auwerx J (1996) PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 15:5336-5348.
17. Tai T-AC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC and Graves RA (1996) Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 271:29909-29914.
18. Tontonoz P, Hu E, Devine J, Beale EG and Spiegelman BM (1995) PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351-357.
19. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA and Lehmann JM (1996) Structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668.
20. Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KWM, Mossakowska D, Murphy GJ, Roxbee Cox L and Smith SA (1998) Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284: 751-759.